Phase II study of sunitinib in men with advanced prostate cancer

Background: This study explored the efficacy and tolerability of sunitinib, an inhibitor of tyrosine kinase receptors, in men with castration-resistant prostate cancer (CRPC). Methods: Men with no prior chemotherapy (group A) and men with docetaxel (Taxotere)-resistant prostate cancer (group B) were...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Dror Michaelson, M., Regan, M. M., Oh, W. K., Kaufman, D. S., Olivier, K., Michaelson, S. Z., Spicer, B., Gurski, C., Kantoff, P. W., Smith, M. R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2009
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2674960/
https://ncbi.nlm.nih.gov/pubmed/19403935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdp111
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi